Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - a dose-ranging study
RCT
OA: closed
CC0
⤵ 8 in-corpus citations
AI-generated summary
This dose-ranging study investigated continuous-combined hormone therapy using estradiol valerate and dienogest for menopausal symptom management.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVES: To determine the progestational efficacy of continuous treatment with various doses of dienogest, combined with oestradiol valerate, on the basis of endometrial histology, effect on climacteric symptoms and bleeding profile in postmenopausal women.
METHODS: Patients were randomised to one of five fixed-combination treatments, oestradiol valerate 2.0 mg plus dienogest 0.5, 1.0, 2.0, 3.0 or 4.0 mg. Efficacy was assessed by endometrial biopsy, menstrual charts and change in climacteric symptoms.
RESULTS: The endometrium was classified as atrophic in 20.0, 31.3, 25.0, 55.6 and 57.1% of patients in the 0.5, 1.0, 2.0, 3.0 and 4.0 mg dienogest groups, respectively. The frequency of uterine bleeding was dose-dependent. The most favourable bleeding profile was seen in the 3.0 mg dienogest group, whereas the lower doses of dienogest had advantages with respect to the efficacy of the combined preparation.
CONCLUSIONS: Dienogest 2.0 and 3.0 mg are the optimal doses for combination with 2.0 mg oestradiol valerate for continuous-combined hormone replacement therapy.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (14)
- doi:10.1016/0029-7844(95)00115-8 via openalex
- doi:10.1016/0378-5122(81)90006-2 via openalex
- doi:10.1016/0002-9378(87)90170-0 via openalex
- doi:10.1097/00004424-198604000-00017 via openalex
- doi:10.1016/0002-9378(90)90917-v via openalex
- doi:10.1515/9783112422168-021 via openalex
- doi:10.1016/0378-5122(91)90281-t via openalex
- doi:10.1016/0378-5122(84)90022-7 via openalex
- doi:10.1016/s0015-0282(16)55667-2 via openalex
- doi:10.1016/0002-9378(79)90821-4 via openalex
- W2413595473 via openalex
- doi:10.1016/0378-5122(88)90063-1 via openalex
- doi:10.1016/s0140-6736(88)90824-0 via openalex
- doi:10.1016/0378-5122(89)90122-9 via openalex
Cited by (6)
- Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone 2017
- Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial 2015
- Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest 2011
- Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial 2008
- Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia 2003
- Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints 2001
Source provenance
- openalex
- last seen: 2026-05-11T05:50:48.314143+00:00
- pubmed
- last seen: 2026-10-08T20:59:30.381419+00:00
- unpaywall
- last seen: 2026-10-14T06:23:58.021457+00:00
License: CC0
· commercial use OK